S
Splash Pharmaceuticals
Splash Pharmaceuticals is a clinical stage oncology company
About Splash Pharmaceuticals
Splash Pharmaceuticals is a clinical stage company specializing in oncology and arthritis therapies. The company leverages its extensive experience and data to develop innovative treatments targeting CD44, a protein involved in cell communication and migration. Splash's lead candidate, SPL 108, has shown promising results in multiple clinical trials, demonstrating both safety and efficacy in over 100 human subjects. The company primarily serves patients suffering from various cancer types and arthritis, operating within the biopharmaceutical market. Splash Pharmaceuticals generates revenue through the development and potential commercialization of its therapeutic candidates, aiming to bring new, effective treatments to market.
Source: Dealroom company dataAt a glance
- Founded
- 2001
- Headquarters
- San Diego, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- SCSolstice Capital
- HBHamilton BioVentures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Splash Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Splash Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.